Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IDYA
stocks logo

IDYA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.927
-37.75%
--
--
-0.930
+13.41%
--
--
-0.938
+6.63%
Estimates Revision
The market is revising Upward the revenue expectations for IDEAYA Biosciences, Inc. (IDYA) for FY2025, with the revenue forecasts being adjusted by 314.18% over the past three months. During the same period, the stock price has changed by 32.58%.
Revenue Estimates for FY2025
Revise Upward
up Image
+314.18%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-65.21%
In Past 3 Month
Stock Price
Go Up
up Image
+32.58%
In Past 3 Month
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 49.19 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 49.19 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
2 Hold
0 Sell
Strong Buy
Current: 36.010
sliders
Low
30.00
Averages
49.19
High
79.00
Current: 36.010
sliders
Low
30.00
Averages
49.19
High
79.00
Truist
Buy
initiated
$59
2025-11-24
Reason
Truist
Price Target
$59
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of Ideaya Biosciences with a Buy rating and $59 price target. The company's lead asset, darovasertib/PKCi has a major valuation inflection point approaching from the phase II/III MUM's PFS topline readout that could support accelerated approval, the analyst tells investors in a research note. Based on strong phase II data and positive feedback from key opinion leaders, Truist sees favorable reward-risk profile for the upcoming phase II/III PFS topline readout with roughly 85% probability.
Mizuho
Graig Suvannavejh
Outperform
maintain
$44 -> $46
2025-11-11
Reason
Mizuho
Graig Suvannavejh
Price Target
$44 -> $46
2025-11-11
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Ideaya Biosciences to $46 from $44 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q3 report.
JPMorgan
Overweight
maintain
$74 -> $79
2025-10-23
Reason
JPMorgan
Price Target
$74 -> $79
2025-10-23
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Ideaya Biosciences to $79 from $74 and keeps an Overweight rating on the shares. The firm cites an increased probability of success for darovasertib in the neoadjuvant setting, to 70% from 60%, for the target bump. It estimates peak sales of darovasertib to be $500M in the U.S. alone. JPMorgan sees share upside for Ideaya into the metastatic uveal melanoma update.
RBC Capital
Outperform
maintain
$38 -> $41
2025-10-21
Reason
RBC Capital
Price Target
$38 -> $41
2025-10-21
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Ideaya Biosciences to $41 from $38 and keeps an Outperform rating on the shares. Ideaya Biosciences presented data on eye and visual acuity preservation from daro in the neo-adjuvant setting, suggesting evidence of very impressive anti-tumor efficacy leading to meaningful survival benefits, eye preservation and visual benefits, increasing the likelihood that upcoming phase III trials will read out positively, the analyst tells investors in a research note.
Goldman Sachs
Neutral
maintain
$27 -> $30
2025-10-21
Reason
Goldman Sachs
Price Target
$27 -> $30
2025-10-21
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on Ideaya Biosciences to $30 from $27 and keeps a Neutral rating on the shares. New data for Ideaya's darovasertib in first-line metastatic uveal melanoma showed median overall survival of 21.1 months, exceeding base expectations of 18-21 months and likely driving stock outperformance, the analyst tells investors in a resarch note. The results support optimism for the ongoing Phase 2/3 trial ahead of 2026 progression free survival data, though uncertainty remains regarding outcomes in the HLA-A2 negative subgroup, Goldman says.
JPMorgan
Anupam Rama
Overweight
maintain
$74
2025-09-25
Reason
JPMorgan
Anupam Rama
Price Target
$74
2025-09-25
maintain
Overweight
Reason
JPMorgan analyst Anupam Rama added a "Positive Catalyst Watch" on shares of Ideaya Biosciences into the updates for darovasertib. The firm keeps an Overweight rating on the shares with a $74 price target. After hosting a call with management, JPMorgan sees "plenty of value creating events" in the near-term for Ideaya. Darovasertib updates should continue to underscore the drug's "compelling emerging profile," the analyst tells investors in a research note. JPMorgan continues to see Ideaya shares as undervalued on darovasertib alone.
See All Ratings

Valuation Metrics

The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is -9.63, compared to its 5-year average forward P/E of -11.62. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.62
Current PE
-9.63
Overvalued PE
-6.76
Undervalued PE
-16.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.78
Undervalued EV/EBITDA
-15.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
87.77
Current PS
0.00
Overvalued PS
182.25
Undervalued PS
-6.71
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IDYA News & Events

Events Timeline

(ET)
2025-12-01
06:22:00
Ideaya Biosciences Receives FDA Clearance to Initiate Phase 1 Trial for IDE034
select
2025-10-20 (ET)
2025-10-20
06:39:12
Ideaya Biosciences unveils clinical findings from the OptimUM-09 trial
select
2025-10-20
06:05:17
Ideaya Biosciences announces overall survival results from darovasertib study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
08:30 AMBusinesswire
Biocytogen's Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
  • Clinical Trial Approval: IDEAYA has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, with patient enrollment expected to begin in Q1 2026, marking a significant milestone for Biocytogen in the development of bispecific antibody-drug conjugates (ADCs).
  • Technical Validation: IDE034, a bispecific B7H3/PTK7 TOP1 ADC independently developed by Biocytogen, will drive subsequent clinical development following its licensing, showcasing Biocytogen's technical capabilities in bispecific ADC discovery and development.
  • Anti-Tumor Activity: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating its strong anti-tumor activity and potential to offer new therapeutic options for patients.
  • Combination Strategy Exploration: IDEAYA plans to explore combination strategies with its PARG inhibitor IDE161 to enhance response durability and intends to present additional preclinical data supporting the combination rationale at a major medical conference in H1 2026.
[object Object]
Preview
9.0
08:30 AMBusinesswire
Biocytogen's Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
  • Clinical Trial Approval: IDEAYA has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, with patient enrollment expected to begin in Q1 2026, marking a significant milestone for Biocytogen in the development of bispecific antibody-drug conjugates (ADCs).
  • Technical Validation: IDE034, a bispecific B7H3/PTK7 TOP1 ADC independently developed by Biocytogen and licensed to IDEAYA, will support clinical development and showcase Biocytogen's technical capabilities in bispecific ADC discovery and development.
  • Antitumor Potential: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating its strong antitumor activity and broad clinical application potential.
  • Future Development: Biocytogen will continue to provide high-quality source antibodies through RenBiologics to support clinical translation and actively explore additional early-stage assets for external licensing opportunities, further advancing the company's strategic positioning in the biotechnology sector.
[object Object]
Preview
9.0
08:12 AMNewsfilter
Biocytogen Partner IDEAYA Receives FDA Clearance for Phase 1 Trial of IDE034
  • Clinical Trial Approval: Biocytogen's partner IDEAYA Biosciences has received FDA clearance to initiate a Phase 1 clinical trial for IDE034, expected to begin patient enrollment in Q1 2026, marking a significant milestone that could provide new therapies for various tumor patients.
  • Technical Validation: IDE034, as a first-in-class B7H3/PTK7 bispecific antibody-drug conjugate, showcases Biocytogen's technical capabilities in bispecific ADC discovery and development, further solidifying its competitive position in the biopharmaceutical sector.
  • Clinical Potential: Preclinical studies have demonstrated that IDE034 monotherapy induces deep and durable tumor regressions in multiple B7H3/PTK7-positive tumor models, indicating strong anti-tumor activity, with future plans to explore combination strategies with PARG inhibitor IDE161 to enhance efficacy.
  • Market Outlook: The co-expression rates of B7H3 and PTK7 in lung, colorectal, and head and neck cancers are approximately 30%, 46%, and 27%, respectively, indicating the broad clinical application potential of IDE034, while Biocytogen will continue to provide high-quality antibodies through RenBiologics to support clinical translation.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is IDEAYA Biosciences Inc (IDYA) stock price today?

The current price of IDYA is 36.01 USD — it has increased 4.86 % in the last trading day.

arrow icon

What is IDEAYA Biosciences Inc (IDYA)'s business?

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

arrow icon

What is the price predicton of IDYA Stock?

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 49.19 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?

IDEAYA Biosciences Inc revenue for the last quarter amounts to 207.83M USD, decreased % YoY.

arrow icon

What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?

IDEAYA Biosciences Inc. EPS for the last quarter amounts to 1.33 USD, decreased -321.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for IDEAYA Biosciences Inc (IDYA)'s fundamentals?

The market is revising Upward the revenue expectations for IDEAYA Biosciences, Inc. (IDYA) for FY2025, with the revenue forecasts being adjusted by 314.18% over the past three months. During the same period, the stock price has changed by 32.58%.
arrow icon

How many employees does IDEAYA Biosciences Inc (IDYA). have?

IDEAYA Biosciences Inc (IDYA) has 131 emplpoyees as of December 05 2025.

arrow icon

What is IDEAYA Biosciences Inc (IDYA) market cap?

Today IDYA has the market capitalization of 3.16B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free